MX2021015996A - Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2). - Google Patents

Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).

Info

Publication number
MX2021015996A
MX2021015996A MX2021015996A MX2021015996A MX2021015996A MX 2021015996 A MX2021015996 A MX 2021015996A MX 2021015996 A MX2021015996 A MX 2021015996A MX 2021015996 A MX2021015996 A MX 2021015996A MX 2021015996 A MX2021015996 A MX 2021015996A
Authority
MX
Mexico
Prior art keywords
azaindazoles
indazoles
lrrk2 inhibitors
lrrk2
inhibitors
Prior art date
Application number
MX2021015996A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Bradley Schwarz
Daniele Andreotti
Lombaert Stéphane De
Elena Serra
Albert W Garofalo
Fabio Maria Sabbatini
Silvia Bernardi
Marco Migliore
Federica Budassi
Claudia Beato
Original Assignee
Escape Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escape Bio Inc filed Critical Escape Bio Inc
Publication of MX2021015996A publication Critical patent/MX2021015996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2021015996A 2019-07-11 2020-07-10 Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2). MX2021015996A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872891P 2019-07-11 2019-07-11
US201962937979P 2019-11-20 2019-11-20
PCT/US2020/041506 WO2021007477A1 (en) 2019-07-11 2020-07-10 Indazoles and azaindazoles as lrrk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2021015996A true MX2021015996A (es) 2022-06-08

Family

ID=71787214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015996A MX2021015996A (es) 2019-07-11 2020-07-10 Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).

Country Status (12)

Country Link
US (2) US11427558B1 (enExample)
EP (1) EP3997081A1 (enExample)
JP (1) JP2022540200A (enExample)
KR (1) KR20220045954A (enExample)
CN (1) CN114450274A (enExample)
AU (1) AU2020311940A1 (enExample)
BR (1) BR112022000325A2 (enExample)
CA (1) CA3145305A1 (enExample)
IL (1) IL288903A (enExample)
MX (1) MX2021015996A (enExample)
TW (1) TW202116754A (enExample)
WO (1) WO2021007477A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072387B (zh) * 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2022155419A1 (en) * 2021-01-15 2022-07-21 ESCAPE Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
WO2022271840A1 (en) * 2021-06-22 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Selective indazole lrrk2 inhibitors and methods for use thereof
JP2026524104A (ja) * 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物
CN117186066B (zh) * 2023-09-08 2025-07-22 中国药科大学 吲唑类alk5抑制剂及其制备方法与用途
WO2025087274A1 (zh) 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3917662B2 (ja) 1996-02-14 2007-05-23 日立化成工業株式会社 非複屈折性光学用樹脂組成物及びこれを用いた光学用素子
KR100338610B1 (ko) 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
JP4594925B2 (ja) 2003-02-28 2010-12-08 ニッポネックス インコーポレイテッド 増殖亢進性、血管新生性及び炎症性疾患の治療に有用な２−オキソ−１，３，５−パーヒドロトリアザピン誘導体
EP1602647B1 (en) 2003-03-07 2013-10-16 Santen Pharmaceutical Co., Ltd. Novel compound having 4-pyridylalkylthio group as substituent
EP1617840A4 (en) 2003-05-01 2008-08-20 Bristol Myers Squibb Co PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US20080293716A1 (en) 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
WO2006032851A1 (en) 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
US7528132B2 (en) 2005-01-26 2009-05-05 Schering Corporation Kinase inhibitors
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
DE102005014089A1 (de) 2005-03-22 2006-09-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
ES2371774T3 (es) 2005-06-03 2012-01-10 Abbott Laboratories Derivados de ciclobutilamina.
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
CN102633783A (zh) 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
EP1984354B1 (en) 2006-02-16 2009-08-05 Syngeta Participations AG Pesticides containing a bicyclic bisamide structure
CA2645434A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceutical Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
GB0716414D0 (en) 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009035951A2 (en) 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8324219B2 (en) 2007-09-20 2012-12-04 Synta Pharmaceuticals Corp. Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
US8362056B2 (en) 2007-11-05 2013-01-29 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
WO2009073788A1 (en) 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CA2722704A1 (en) 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
US8329907B2 (en) 2009-04-02 2012-12-11 Merck Patent Gmbh Autotaxin inhibitors
CA2774981A1 (en) 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
US20120202814A1 (en) 2009-10-02 2012-08-09 Università Degli Studi Di Siena Compounds with ddx3 inhibitory activity and uses thereof
WO2011123937A1 (en) 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US20130053382A1 (en) 2010-04-30 2013-02-28 Sunil Paliwal Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
CN104478882A (zh) 2010-09-14 2015-04-01 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
KR101566091B1 (ko) * 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
EP2694060A4 (en) 2011-04-01 2014-09-10 Univ Utah Res Found SUBSTITUTED 3- (1H-BENZO- {D} -IMIDAZOL-2-YL-) 1H-INDAZOL ANALOGUE AS PDK1 KINASE INHIBITOR
WO2012162254A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
EP2773645A1 (en) 2011-11-01 2014-09-10 F.Hoffmann-La Roche Ag Imidazopyridazine compounds
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2802324A4 (en) 2012-01-09 2015-07-15 X Rx Inc BENZHYDROL-PYRAZOLE DERIVATIVES WITH KINASE-INHIBITORY EFFECT AND USES THEREOF
WO2013151938A1 (en) 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function
US8962322B2 (en) 2012-12-03 2015-02-24 City Of Hope Enhancers of induced pluripotent stem cell reprogramming
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20160024071A1 (en) 2013-03-15 2016-01-28 Elan Pharmaceuticals, Llc Inhibitors of lrrk2 kinase activity
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
KR20160015221A (ko) 2013-06-06 2016-02-12 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
HK1220976A1 (zh) 2013-06-21 2017-05-19 F. Hoffmann-La Roche Ag 作为rorc调节剂的芳基磺内酰胺衍生物
CU24398B1 (es) 2013-08-02 2019-04-04 Pfizer 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AU2014369053B2 (en) 2013-12-20 2019-03-14 Institute For Drug Discovery, Llc Substituted amino triazoles, and methods using same
US10954240B2 (en) 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20160113931A1 (en) 2014-10-24 2016-04-28 University Of Macau Method of treating and/or preventing neurodegenerative diseases
HK1243636A1 (zh) 2014-11-18 2018-07-20 Rutgers, The State University Of New Jersey 用於治疗代谢疾病和癌症的新的线粒体解偶联剂
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10766860B2 (en) 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
US10975081B2 (en) * 2015-07-23 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017049409A1 (en) 2015-09-25 2017-03-30 The Centre For Drug Research And Development Compositions for promoting readthrough of premature termination codons, and methods of using the same
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
US10933068B2 (en) * 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
TWI800498B (zh) 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
CN110248936A (zh) 2017-01-25 2019-09-17 葛兰素史密斯克莱知识产权发展有限公司 化合物
BR112019015273A2 (pt) 2017-01-25 2020-04-14 Glaxosmithkline Ip Dev Ltd compostos
WO2018137607A1 (en) 2017-01-25 2018-08-02 Glaxosmithkline Intellectual Property Development Limited Compounds
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3621962A4 (en) 2017-05-10 2020-12-09 Forge Therapeutics, Inc. ANTIBACTERIAL COMPOUNDS
CN107176932B (zh) 2017-05-26 2020-06-05 中国药科大学 苯并恶嗪酮衍生物及其制备方法和用途
WO2019002624A1 (de) 2017-06-30 2019-01-03 Kleuser, Burkhard Mittel zur therapie entzündlicher darmerkrankungen
KR102687118B1 (ko) 2017-08-16 2024-07-19 벤더르빌트 유니버시티 Mglur4 알로스테릭 증강제로서의 인다졸 화합물, 조성물, 및 신경 기능장애 치료 방법
EP3694330B1 (en) 2017-10-11 2023-04-19 Merck Sharp & Dohme LLC Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US11174248B2 (en) 2017-10-11 2021-11-16 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
AU2018361971A1 (en) 2017-11-03 2020-06-04 Universite De Montreal Compounds and use thereof in the expansion of stem cells and/or progenitor cells
US20210261553A1 (en) 2018-05-15 2021-08-26 E-Scape Bio, Inc. Fused tetrazoles as lrrk2 inhibitors
EP3873471B1 (en) 2018-10-31 2025-12-31 Merck Sharp & Dohme LLC N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS: PHARMACEUTICAL COMPOSITIONS AND THEIR USES
WO2020135513A1 (zh) 2018-12-25 2020-07-02 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
US20220162192A1 (en) 2019-03-21 2022-05-26 ESCAPE Bio, Inc. Indazoles as lrrk2 inhibitors
US20210386721A1 (en) 2019-05-10 2021-12-16 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted phenylpropenyl pyridine derivatives, their preparation and pharmaceutical applications
WO2020247298A2 (en) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2021050688A1 (en) 2019-09-10 2021-03-18 X-Chem, Inc. Compounds and uses thereof
CN114072387B (zh) 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用
CA3181786A1 (en) 2020-05-01 2021-11-04 The Regents Of The University Of California Inhibitors of alpha 2 beta 1 integrin and methods of use thereof

Also Published As

Publication number Publication date
BR112022000325A2 (pt) 2022-03-15
WO2021007477A1 (en) 2021-01-14
US11427558B1 (en) 2022-08-30
AU2020311940A1 (en) 2022-02-03
KR20220045954A (ko) 2022-04-13
IL288903A (en) 2022-02-01
JP2022540200A (ja) 2022-09-14
US20230077268A1 (en) 2023-03-09
CN114450274A (zh) 2022-05-06
EP3997081A1 (en) 2022-05-18
TW202116754A (zh) 2021-05-01
CA3145305A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
MX2025003445A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
ZA202310316B (en) Fluoroalkyl-oxadiazoles and uses thereof
MA62580B1 (fr) Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
ZA202007007B (en) Mcl-1 inhibitors
BR112022000325A2 (pt) Indazois e azaindazois como inibidores de lrrk2
PH12018500397A1 (en) Compounds and compositions useful for treating disorders related to ntrk
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2021006831A (es) Inhibidores de alk5.
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2017012729A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).